Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
Autor: | Lorraine Blaise, Maxime Benhamou, Christian Sengel, Olivier Sutter, Julien Ghelfi, Yann Teyssier, Jean-Charles Nault, Nathalie Ganne-Carrié, Mélodie Abousalihac, Gaël S. Roth, Thomas Decaens, Olivier Seror, Arnaud Seigneurin |
---|---|
Rok vydání: | 2021 |
Předmět: |
Cancer Research
medicine.medical_specialty Cirrhosis medicine.medical_treatment survival lcsh:RC254-282 Gastroenterology Article trans-arterial chemoembolization 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Embolization bland embolization intermediate stage tumor response business.industry hepatocellular carcinoma Odds ratio lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Oncology Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Hepatocellular carcinoma Propensity score matching Bland Embolization Lipiodol 030211 gastroenterology & hepatology business medicine.drug |
Zdroj: | Cancers, Vol 13, Iss 812, p 812 (2021) Cancers Volume 13 Issue 4 |
ISSN: | 2072-6694 |
Popis: | Simple Summary In this study, efficacy and safety of embolization alone and trans-arterial chemoembolization were compared in 265 patients with intermediate stage hepatocellular carcinoma. Trans-arterial chemoembolization was associated with a significant increase of complete radiological response, but without significant impact on overall response, and survival outcomes after propensity score matching. Both techniques showed similar safety profiles. To this day, embolization alone and trans-arterial chemoembolization are two available options in the treatment of intermediate stage hepatocellular carcinoma. Abstract No definitive conclusion could be reached about the role of chemotherapy in adjunction of embolization in the treatment of hepatocellular carcinoma (HCC). We aim to compare radiological response, toxicity and long-term outcomes of patients with hepatocellular carcinoma (HCC) treated by trans-arterial bland embolization (TAE) versus trans-arterial chemoembolization (TACE). We retrospectively included 265 patients with HCC treated by a first session of TACE or TAE in two centers. Clinical and biological features were recorded before the treatment and radiological response was assessed after the first treatment using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Correlation between the treatment and overall, progression-free and transplantation-free survival was performed after adjustment using a propensity score matching: 86 patients were treated by bland embolization and 179 patients by TACE, including 44 patients with drug-eluting beads and 135 with lipiodol TACE, 89.8% of patients were male with a median age of 65 years old. Cirrhosis was present in 90.9% of patients with a Child Pugh score A in 84% of cases. After adjustment, no difference in the rate of AE, including liver failure, was observed between the two treatments. TACE was associated with a significant increase in complete radiological response (odds ratio (OR) = 8.5 (95% confidence interval (CI): 2.8–25.4)) but not in the overall response rate (OR = 2.2 (95% CI = 0.8–5.8)). No difference in terms of overall survival (p = 0.3905), progression-free survival (p = 0.4478) and transplantation-free survival (p = 0.9020) was observed between TACE and TAE. TACE was associated with a higher rate of complete radiological response but without any impact on overall radiological response, progression-free survival and overall survival compared to TAE. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |